Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Hydrocortisone - Diurnal

Drug Profile

Hydrocortisone - Diurnal

Alternative Names: Alkindi; ALKINDI SPRINKLE; Chronocort; Hydrocortisone extended release - Diurnal; Infacort

Latest Information Update: 23 Oct 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Diurnal
  • Developer Diurnal; EffRx; Emerge Health; Eton Pharmaceuticals; Medison Pharma
  • Class Anti-inflammatories; Antiallergics; Glucocorticoids; Pregnenediones; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Congenital adrenal hyperplasia; Adrenal insufficiency
  • New Molecular Entity No

Highest Development Phases

  • Marketed Adrenal insufficiency
  • Registered Congenital adrenal hyperplasia

Most Recent Events

  • 21 Oct 2020 Diurnal Group and EffRx Pharmaceuticals enter into a licensing agreement for the registration and commercialisation of hydrocortisone in Switzerland
  • 21 Oct 2020 Preregistration for Adrenal insufficiency (In adolescents, In children, In infants, In neonates) in Switzerland (PO)
  • 21 Oct 2020 EffRx intends to launch Alkindi in Switzerland for Adrenal insufficiency (In adolescents, In children, In infants, In neonates) in 2022
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top